CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in Barostim™, an innovative extravascular neuromodulation device for cardiovascular diseases, has announced its plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025.
The company will host a conference call and webcast at 4:30pm Eastern Time on the same day to review the results. Investors can access the webcast through the company's investor relations website at ir.cvrx.com. For telephone access, U.S. callers can dial 1-877-704-4453, while international callers should use 1-201-389-0920.
CVRx (NASDAQ: CVRX), un'azienda medica in fase commerciale specializzata in Barostim™, un dispositivo innovativo di neuromodulazione extravascolare per le malattie cardiovascolari, ha annunciato i suoi piani per rilasciare i risultati finanziari e operativi del quarto trimestre 2024 dopo la chiusura del mercato martedì 4 febbraio 2025.
L'azienda ospiterà una teleconferenza e una trasmissione in diretta alle 16:30 ora orientale nello stesso giorno per rivedere i risultati. Gli investitori possono accedere alla trasmissione in diretta tramite il sito web delle relazioni con gli investitori dell'azienda all'indirizzo ir.cvrx.com. Per l'accesso telefonico, i chiamanti statunitensi possono comporre il numero 1-877-704-4453, mentre i chiamanti internazionali dovrebbero utilizzare il numero 1-201-389-0920.
CVRx (NASDAQ: CVRX), una compañía de dispositivos médicos en etapa comercial especializada en Barostim™, un innovador dispositivo de neuromodulación extravascular para enfermedades cardiovasculares, ha anunciado sus planes para publicar los resultados financieros y operativos del cuarto trimestre de 2024 después del cierre del mercado el martes 4 de febrero de 2025.
La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo a las 4:30 p.m. hora del Este el mismo día para revisar los resultados. Los inversionistas pueden acceder a la transmisión en vivo a través del sitio web de relaciones con inversionistas de la compañía en ir.cvrx.com. Para el acceso telefónico, los llamantes de EE. UU. pueden marcar el 1-877-704-4453, mientras que los llamantes internacionales deben usar el 1-201-389-0920.
CVRx (NASDAQ: CVRX)는 심혈관 질환을 위한 혁신적인 외부 신경 조절 장치인 Barostim™을 전문으로 하는 상업 단계 의료 기기 회사로, 2024년 4분기 재무 및 운영 결과를 2025년 2월 4일 화요일 시장 마감 후 발표할 계획이라고 밝혔습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 결과를 검토하기 위해 컨퍼런스 콜 및 웹 캐스트를 개최할 예정입니다. 투자자들은 회사의 투자자 관계 웹사이트 ir.cvrx.com을 통해 웹 캐스트에 접근할 수 있습니다. 전화 접근의 경우, 미국 발신자는 1-877-704-4453로 전화할 수 있으며, 국제 발신자는 1-201-389-0920을 사용해야 합니다.
CVRx (NASDAQ: CVRX), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans Barostim™, un dispositif innovant de neuromodulation extravasculaire pour les maladies cardiovasculaires, a annoncé ses plans pour publier les résultats financiers et opérationnels du quatrième trimestre 2024 après la fermeture du marché le mardi 4 février 2025.
L'entreprise animera une conférence téléphonique et un webinaire à 16h30, heure de l'Est, le même jour pour examiner les résultats. Les investisseurs peuvent accéder au webinaire via le site web des relations investisseurs de l'entreprise à l'adresse ir.cvrx.com. Pour un accès téléphonique, les appelants américains peuvent composer le 1-877-704-4453, tandis que les appelants internationaux doivent utiliser le 1-201-389-0920.
CVRx (NASDAQ: CVRX), ein medizinisches Geräteunternehmen in der kommerziellen Phase, das auf Barostim™ spezialisiert ist, ein innovatives extravasales Neuromodulationsgerät zur Behandlung von Herz-Kreislauf-Erkrankungen, hat seine Pläne bekannt gegeben, die Finanz- und Betriebsergebnisse des vierten Quartals 2024 nach Börsenschluss am Dienstag, den 4. Februar 2025, zu veröffentlichen.
Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast zur Überprüfung der Ergebnisse abhalten. Investoren können über die Investor-Relations-Website des Unternehmens unter ir.cvrx.com auf den Webcast zugreifen. Für den telefonischen Zugang können US-Anrufer die Nummer 1-877-704-4453 wählen, während internationale Anrufer die Nummer 1-201-389-0920 verwenden sollten.
- None.
- None.
MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
651-338-6204
emeyers@cvrx.com
FAQ
When will CVRx (CVRX) release its Q4 2024 earnings?
How can investors join the CVRx (CVRX) Q4 2024 earnings call?
What time is the CVRx (CVRX) Q4 2024 earnings conference call?
What is CVRx's (CVRX) main product?
